Korean J Pediatr Hematol Oncol.
2005 Apr;12(1):18-27.
Hematopoietic Stem Cell Transplantation for Children with Malignant Lymphoma in Korea: Multicenter Retrospective Study
- Affiliations
-
- 1Department of Pediatrics, College of Medicine, Yonsei University, Seoul, Korea. cj@yumc.yonsei.ac.kr
- 2Department of Pediatrics, Seoul National University, Seoul, Korea.
- 3Department of Pediatrics, Chonnam University, Gwangju, Korea.
- 4Department of Pediatrics, Sungkyunkwan University, Seoul, Korea.
- 5Department of Pediatrics, The Catholic University of Korea, Seoul, Korea.
- 6Department of Pediatrics, Ajou University, Suwon, Korea.
- 7Department of Pediatrics, Yeungnam University, Daegu, Korea.
- 8Department of Pediatrics, Ulsan University, Seoul, Korea.
- 9Department of Pediatrics, Kosin University, Busan, Korea.
- 10Department of Pediatrics, Dong-A University, Busan, Korea.
- 11Department of Pediatrics, Ewha Womans University, Seoul, Korea.
Abstract
- PURPOSE
Children with Malignant lymphoma who is in the advanced stage at diagnosis or relapses during treatment have a poor prognosis. Recently, hematopoietic stem cell transplantation (HSCT) for advanced stage or refractory/relapsed lymphoma performed frequently. However, the role for HSCT for children with malignant lymphoma is still controversial. In this study, we reviewed children with malignant lymphoma who received HSCT and analyzed the results. METHODS: Questionnaires were made and sent to a group of teaching hospitals, with a return of 37 questionnaires from 11 hospitals. 33 patients with Non-Hodgkin lymphoma (NHL) and 4 patients with Hodgkin disease (HD) who received HSCT from 1997 to 2004 in Korea were enrolled in this study. Disease state at diagnosis, relapses during treatment, disease state at HSCT, and survival record were analyzed. All Data were reviewed with the questionnaires from the 11 teaching hospitals. RESULTS: Four patients with HD received HSCT at the 2nd complete remission after relapse. Survival rate for HD was 100% and their follow up duration ranged from 0.2 to 6.2 years (median 2.4 years). The 2-year survival rate for NHL was 68.1+/-9.0% and their follow up duration ranged from 0.1 to 7.6 years (median 1.5 years). The 2-year survival rate in patients with advanced stage at diagnosis and in relapsed/refractory patients were 83.6+/-1.1% and 55.9+/-12.9%, respectively (P=0.12). The mortality asssociated with HSCT was only 1 case, and most of the transplantation related complications did not resulted in death. CONCLUSION: Our results suggest that high dose chemotherapy followed by HSCT in children with malignant lymphoma is a safe procedure, which at the same time improves the results of standard treatment.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Two Cases of Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation
- Opening the era of in vivo xenotransplantation model for hematopoietic stem cell transplantation
- Hematopoietic Stem Cell Transplantation
- Autoimmune Diseases after Autologous Hematopoietic Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma
- Hematopoietic Stem Cell Transplantation in Inborn Error of Metabolism
